Petco Health & Wellness Company, Inc.

For the period ended Feb 1, 2025. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2025

WOOF$2.93-5.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEM ENTS OF CASH FLOWS

	Fiscal years ended
	February 1,2025	February 3,2024	January 28,2023
	(52 weeks)	(53 weeks)	(52 weeks)
Cash flows from operating activities:
Net (loss) income	$(101,816)	$(1,280,210)	$89,910
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	199,727	200,782	193,828
Amortization of debt discounts and issuance costs	4,896	4,972	4,940
Provision for deferred taxes	(30,492)	(53,549)	(893)
Equity-based compensation expense	50,212	81,859	60,784
Impairments, write-offs and losses on sale of fixed and other assets	8,790	2,833	1,992
Loss on partial extinguishment of debt	—	920	—
Income from equity method investees	(18,669)	(16,188)	(12,976)
Amounts reclassified out of accumulated other comprehensive (loss) income (Note 8)	(3,146)	(488)	168
Goodwill impairment	—	1,222,524	—
Non-cash operating lease costs	414,396	429,056	422,792
Other non-operating (income) loss	(4,800)	(4,727)	12,667
Changes in assets and liabilities:
Receivables	4,178	5,211	6,038
Merchandise inventories	30,767	(32,072)	22,681
Prepaid expenses and other assets	(3,960)	(8,009)	(5,933)
Accounts payable and book overdrafts	8,484	103,919	(22,763)
Accrued salaries and employee benefits	56,981	11,347	(51,427)
Accrued expenses and other liabilities	(12,455)	(8,495)	13,616
Operating lease liabilities	(418,219)	(446,981)	(386,259)
Other long-term liabilities	(7,201)	3,015	(3,162)
Net cash provided by operating activities	177,673	215,719	346,003
Cash flows from investing activities:
Cash paid for fixed assets	(127,990)	(225,598)	(278,020)
Cash paid for acquisitions, net of cash acquired (Note 3)	(629)	(6,725)	(9,640)
Cash paid for interest in veterinary joint venture (Note 1)	—	—	(35,000)
Cash paid for investment	(457)	—	—
Proceeds from investments	998	24,878	—
Proceeds from sale of assets	1,369	—	2,336
Cash received from partial surrender of officers' life insurance	2,806	—	—
Net cash used in investing activities	(123,903)	(207,445)	(320,324)
Cash flows from financing activities:
Borrowings under long-term debt agreements	201,000	273,000	123,000
Repayments of long-term debt	(201,000)	(348,000)	(140,000)
Debt refinancing costs	(3,028)	—	—
Payments for finance lease liabilities	(5,707)	(5,925)	(5,083)
Proceeds from employee stock purchase plan and stock option exercises	3,770	4,223	3,796
Tax withholdings on stock-based awards	(6,289)	(8,650)	(15,555)
Proceeds from issuance of common stock	2,500	—	—
Net cash used in financing activities	(8,754)	(85,352)	(33,842)
Net increase (decrease) in cash, cash equivalents and restricted cash	45,016	(77,078)	(8,163)
Cash, cash equivalents and restricted cash at beginning of year	136,649	213,727	221,890
Cash, cash equivalents and restricted cash at end of year	$181,665	$136,649	$213,727
Supplemental cash flow disclosures:
Interest paid, net	$138,618	$142,114	$89,285
Capitalized interest	$729	$1,260	$1,480
Income taxes paid	$34,840	$32,192	$14,443
Supplemental non-cash investing and financing activities disclosures:
Accounts payable and accrued expenses for capital expenditures	$13,005	$18,888	$29,051
Accrued tax withholdings on stock-based awards	$—	$809	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.